No pros available.
No cons available.
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | SMMT | Summit Therapeutics Inc. | 1,349.40 Bn | -1,464.17 | 0.00 | 0.01 Bn |
| 2 | ONC | BeOne Medicines Ltd. | 437.43 Bn | 6,381.20 | 87.97 | 1.90 Bn |
| 3 | VRTX | Vertex Pharmaceuticals Inc / Ma | 116.09 Bn | 31.59 | 9.90 | 1.83 Bn |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | 78.10 Bn | 17.06 | 5.48 | 2.71 Bn |
| 5 | ALNY | Alnylam Pharmaceuticals, Inc. | 55.87 Bn | 1,282.42 | 17.40 | 3.21 Bn |
| 6 | ARGX | Argenx Se | 52.85 Bn | 35.08 | 27,559.65 | - |
| 7 | BNTC | Benitec Biopharma Inc. | 41.75 Bn | -998.33 | 0.00 | 0.00 Bn |
| 8 | INSM | INSMED Inc | 37.80 Bn | -31.93 | 84.56 | 0.74 Bn |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| EV to Assets | 21.01 | 12.31 | |
| EV to Cash from Ops. | -30.49 | 23.25 | |
| EV to Debt | 18.52 | 738.44 | |
| EV to EBIT | -24.45 | -9.16 | |
| EV to EBITDA | -22.44 | 6.95 | |
| EV to Free Cash Flow [EV/FCF] | -30.00 | 21.90 | |
| EV to Market Cap | 1.04 | 65.67 | |
| EV to Revenue | 93.44 | 227.32 | |
| Price to Book Value [P/B] | -13.26 | 22.34 | |
| Price to Earnings [P/E] | -17.70 | -11.77 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Dividend Coverage Ratio | 0.00 | -11.94 | |
| Dividend Payout Ratio % | 0.00 | 0.16 | |
| Dividend per Basic Share | 0.00 | 0.01 | |
| FCF Dividend Payout Ratio % | 0.00 | -0.14 | |
| Interest Coverage | -3.02 | 841.00 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Capex Growth (1y) % | -11.80 | -27.13 | |
| Cash and Equivalents Growth (1y) % | -52.47 | 734.65 | |
| Dividend Growth (1y) % | 0.00 | 0.01 | |
| EBIAT Growth (1y) % | -105.54 | -46.93 | |
| EBITDA Growth (1y) % | -96.91 | -1.68 | |
| EBIT Growth (1y) % | -107.30 | -56.45 | |
| EBT Growth (1y) % | -70.25 | -12.70 | |
| EPS Growth (1y) % | -61.16 | -28.31 | |
| FCF Growth (1y) % | -2,146.53 | -31.90 | |
| Gross Profit Growth (1y) % | -73.67 | 226.84 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Asset Utilization Ratio | 0.26 | 0.14 | |
| Cash Payout Ratio | 0.00 | 0.00 | |
| Cash Ratio | 0.46 | 3.85 | |
| Current Ratio | 0.63 | 7.27 | |
| Debt to Equity Ratio | -0.74 | 0.40 | |
| Interest Cover Ratio | -3.02 | 841.00 | |
| Times Interest Earned | -3.02 | 841.00 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| EBITDA Margin % | -366.10 | -18,234.31 | |
| EBIT Margin % | -324.87 | -18,580.80 | |
| EBT Margin % | -508.76 | -19,488.74 | |
| Gross Margin % | 100.00 | -7.59 | |
| Net Profit Margin % | -508.40 | -19,439.22 |